Oxford Biomedica to acquire ABL Europe to expand global CDMO reach
Oxford Biomedica plc, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), is set to significantly enhance its global presence with the ... Read More
Oxford Biomedica eyes ABL Europe acquisition to bolster cell and gene therapy CDMO operations
Oxford Biomedica plc and Institut Mérieux SA have entered exclusive negotiations concerning Oxford Biomedica's proposed acquisition of ABL Europe SAS. This acquisition, valued at €15 ... Read More